BCR and pulmonary arterial hypertension: Moreover, some serious adverse events, such as cardiovascular toxicity of ponatinib (Singh et al., 2019) and pulmonary hypertension of dasatinib (Guignabert et al., 2016), have limited the application of these agents; meanwhile, the emergence of compound mutations in the BCR::ABL1 kinase region is resistant to all approved TKIs targeting BCR::ABL1 (Khorashad et al., 2013).